SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein ...

The AMPLIFY study [NCT03836261] did not include patients with del (17p), so that doublet is not relevant. The study that used ...

Patients with vitiligo have an increased prevalence of autoimmune comorbidities, including thyroid disorders, psoriasis, and rheumatoid arthritis.

Chimeric antigen receptor T-cell therapy has exhibited “compelling” efficacy and safety in lupus, allowing 84% of patients to ...

The team found that neurons from individuals with postmortem CTE diagnoses had specific abnormal patterns of somatic genome ...

Background Anti-C1q autoantibodies can disrupt normal complement function, contributing to the formation of pathogenic immune ...

T cell therapy has emerged as a powerful new way to treat cancer. By extracting patients' T cells, re-engineering them to ...

J.P. Morgan Securities LLC, Jefferies LLC and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. Oppenheimer & Co. Inc. and Robert W. Baird & Co.

(r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical data support bexobrutideg as potential best-in-class BTK degrader profile Nurix will host an investor ...

The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...

Andrew G. Lee, MD, and Drew Carey, MD, highlight how chronic lymphocytic leukemia can mimic Graves’ orbitopathy, underscoring ...

People with autoimmune skin diseases had significantly better cancer survival outcomes than others. Survival benefits were most notable in people with alopecia areata and Sjögren syndrome. Findings ...